^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FATE-NK100

    i
    Other names: adaptive NK cell cancer immunotherapy, FATE-NK100, FATE NK100
    Associations

    News

    Trials
    Company:
    Fate Therap, University of Minnesota
    Drug class:
    NK cell stimulant, Cell therapy
    Related drugs:
    Associations

    News

    Trials
    almost3years
    FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=44, Completed, Fate Therapeutics | Active, not recruiting --> Completed | N=100 --> 44 | Trial completion date: Oct 2022 --> Dec 2020
    Clinical • Trial completion • Enrollment change • Trial completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • Erbitux (cetuximab) • FATE-NK100
    over4years
    [VIRTUAL] APOLLO: A phase I study of adaptive memory natural killer (NK) cells in recurrent ovarian cancer. (ASCO 2020)
    FATE-NK100 via IP port was tested using 3 dose cohorts ([DC]; 1 × 107 cells/kg; >1 × 107 cells/kg to ≤3 × 107 cells/kg; or >3 × 107 to ≤10 × 107 cells/kg) after lympho-conditioning with fludarabine 25 mg/m2 IV and cyclophosphamide 300 mg/m2 IV on days −6 and −5. IP delivery of FATE-NK100 is safe, with clinical benefit in 3/9 patients treated. The allogeneic product cells persist and have enhanced function compared to patient NK cells for up to 21 days, even after retreatment. This phase I study in recurrent/refractory ovarian cancer shows promise for IP NK cell delivery.
    P1 data
    |
    IFNG (Interferon, gamma)
    |
    fludarabine IV • FATE-NK100 • cyclophosphamide intravenous
    almost5years
    FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=100, Active, not recruiting, Fate Therapeutics | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • Erbitux (cetuximab) • FATE-NK100